
Côte d'Ivoire ALMA Quarterly Report Quarter Four, 2022




Scorecard for Accountability and Action



Commodities Financed		
LLIN financing 2022 projection (% of need)		100
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		4
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)	•	
ACTs in stock (>6 months stock)		
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)	10	100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs an	d C	ovid 19
Scale of Implementation of iCCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)		57
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		54
Vitamin A Coverage 2021 (2 doses)		85
DPT3 coverage 2021 (vaccination among 0-11 month olds)		76
% Population Fully Vaccinated Against COVID-19	Ī.	38

Malaria transmission occurs all year round throughout Côte d'Ivoire, although it is more seasonal in the north of the country. The annual reported number of malaria cases in 2021 was 7,633,965 with 1,276 deaths.

Key



Côte d'Ivoire ALMA Quarterly Report Quarter Four, 2022



Malaria

Global Fund Update

The Global Fund has announced that *Côte* d'Ivoire will receive US\$229.1 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Côte d'Ivoire's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Côte d'Ivoire this is calculated at US\$130.4 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Côte d'Ivoire is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Côte d'Ivoire has successfully raised resources for the financing of LLINs, RDTs, and ACTs in 2022 and has procured enough LLINs to achieve 100% operational coverage of the targeted at-risk population with LLINs. The country has also scaled up implementation of iCCM. There are sufficient stocks of ACTs and RDTs. Côte d'Ivoire has recently reported the results of insecticide resistance testing to WHO and has carried out drug resistance testing since 2018 and has reported the results to WHO. The national strategic plan includes activities targeting refugees. The country has launched the Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Côte d'Ivoire has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Scorecard, however the scorecard is not yet shared through the ALMA Scorecard Hub.

Impact

The annual reported number of malaria cases in 2021 was 7,633,965 with 1,276 deaths.

Key Challenge

 Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and NTDs.

Previous Key Recommended Action

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic	Q4 2022		The NMCP is conducting the retrospective assessment and the MPR in collaboration with partners. Planned routine activities at health facility and community level were implemented including ITN distribution to pregnant women and children under one year. The country has sufficient stocks of ACTs

New Key Recommended Action

Objective	Action Item	Suggested completion timeframe
Impact	Investigate and address the reasons for the increase in estimated malaria incidence between 2015 and 2021	Q4 2023

RMNCAH and NTDs

Progress

The country has made progress on the tracer RMNCAH intervention of vitamin. Côte d'Ivoire has enhanced tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Côte d'Ivoire is measured using a composite index calculated from preventive chemotherapy coverage achieved for onchocerciasis, schistosomiasis, soil transmitted helminths, lymphatic filariasis and trachoma. Preventive chemotherapy coverage in Côte d'Ivoire is low lymphatic filariasis is low (25%), soil transmitted helminths (59%) and for trachoma (62%). Preventive chemotherapy coverage is very good for onchocerciasis (75%) and for schistosomiasis (85%). Overall, the NTD preventive chemotherapy coverage index for Côte d'Ivoire in 2021 is 57 and this represents a decrease compared with the 2020 index value (59).

Previous Key Recommended Actions

Objective	Action Item	Suggested	Progress	Comments - key
		completion timeframe		activities/accomplishments since last quarterly report
RMNCAH ¹ : Optimise quality of care	Ensure that essential RMNCAH services are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH	Q4 2020		The country reports that health services use and demand decreased significantly in 2020 but that the demand for and use of health services has since recovered. NGOs and CBOs carried out outreach and mass-communication awareness-raising activities on COVID-19 including designing and distributing communication materials, radio ads, illustrated fact sheets, illustrated guides, posters, posts on social media and digital platforms. PPE has been distributed to community health workers with additional PPE funded through the Global Fund
NTDs	commodities Ensure that NTD interventions are implemented whilst using Covid-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catchup activities	Q4 2022		The country conducted NTD prevention and control activities whilst respecting COVID-19 preventive measures, including NTD surveillance activities with transmission assessment surveys and mapping for onchocerciasis breeding sites completed in November 2022. The country reached the step of stopping MDAs for trachoma and lymphatic filariasis in most districts, with only one district planning to conduct MDA for Lymphatic Filariasis in January 2023. Other ongoing activities include the pre-transmission assessment and the Morbidity Management and Disability Prevention

¹ RMNCAH metrics, recommended actions and response tracked through WHO

